AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Byline: Michael Barbaro
MedImmune Inc. yesterday said Chief Financial Officer Gregory S. Patrick would step down, less than a month after the Gaithersburg biotechnology company reported dismal first-year sales of its needle-free flu vaccine.
Lori Weiman, a company spokeswoman, said the departure is not tied to the performance of the vaccine, called FluMist. She called it a "personal decision" but would not elaborate. Patrick could not be reached for comment.
Lota S. Zoth, MedImmune's vice president and controller, will serve as acting chief financial officer while the company searches for a permanent replacement. The …